Trevi Therapeutics, Inc. (NASDAQ: TRVI), a pioneering clinical-stage biopharmaceutical company, has captured the attention of investors with its promising drug pipeline and significant potential upside. As the company focuses on the development and commercialization of novel therapies for chronic cough and pruritus, recent analyst ratings suggest an impressive opportunity for growth, highlighting a potential upside of 99.27%.

Operating within the healthcare sector and biotechnology industry, Trevi Therapeutics is headquartered in New Haven, Connecticut. With a market capitalization of $1.4 billion, the company is making strides in the treatment of chronic cough associated with idiopathic pulmonary fibrosis (IPF) and other…